Skip Navigation


Annals of Oncology Advance Access originally published online on April 11, 2005
Annals of Oncology 2005 16(6):923-927; doi:10.1093/annonc/mdi187
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
16/6/923    most recent
mdi187v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Manegold, C.
Right arrow Articles by Vogelzang, N. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Manegold, C.
Right arrow Articles by Vogelzang, N. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

C. Manegold1,*, J. Symanowski2, U. Gatzemeier3, M. Reck3, J. von Pawel4, C. Kortsik5, K. Nackaerts6, P. Lianes7 and N. J. Vogelzang8

1 Heidelberg University Medical Center, Mannheim, Germany; 2 Eli Lilly and Company, Indianapolis, IN, USA; 3 Hospital Grosshansdorf, Grosshansdorf, Germany; 4 Asklepios-Fachklinik, Munchen-Gauting, Germany; 5 St Hildegardis-Krankenhaus, Mainz, Germany; 6 University Hospital Gasthuisberg, Leuven, Belgium; 7 Hospital de Mataro, Barcelona, Spain; 8 Nevada Cancer Institute, Las Vegas, NV, USA

* Correspondence to: Professor Dr C. Manegold, Heidelberg University Medical Center, Department of Surgery, Theodor-Kutzer-Ufer 1–3, 68167 Mannheim, Germany. Tel: +49-8-621-383-2199; Fax: +49-621-383-1430; Email: prof.manegold{at}t-online.de

Background:: A phase III trial in patients with malignant pleural mesothelioma demonstrated a survival advantage for pemetrexed plus cisplatin compared with single-agent cisplatin. Because post-study chemotherapy (PSC) may have influenced the outcome of the trial, we examined its use and association with survival.

Patients and methods:: Eighty-four patients from the pemetrexed plus cisplatin arm and 105 patients from the single-agent cisplatin arm received PSC. Kaplan–Meier survival estimates were compared by treatment groups, and by PSC and non-PSC subgroups.

Results:: The percentage of patients receiving PSC was imbalanced between the treatment arms. Fewer pemetrexed plus cisplatin treated patients received PSC (37.2% versus 47.3%). A multiple regression analysis performed in this trial showed that PSC had a statistically significant correlation with prolonged survival (P <0.01), adjusting for baseline prognostic factors and treatment intervention. The adjusted hazard ratio for PSC over non-PSC subgroups was 0.56 (confidence interval 0.44–0.72).

Conclusions:: PSC in malignant pleural mesothelioma was significantly associated with prolonged survival. It is not known whether the reduced risk of death was associated with PSC or whether patients who had prolonged survival tended to receive more PSC. The pemetrexed plus cisplatin treatment group had a statistically significant survival advantage even though fewer patients from that arm of the trial received PSC. The potentially beneficial role of PSC should be assessed in prospective trials.

Key words: malignant pleural mesothelioma, pemetrexed, second-line chemotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J. Jassem, R. Ramlau, A. Santoro, W. Schuette, A. Chemaissani, S. Hong, J. Blatter, S. Adachi, A. Hanauske, and C. Manegold
Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma
J. Clin. Oncol., April 1, 2008; 26(10): 1698 - 1704.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
British Thoracic Society Standards of Care Committ
BTS statement on malignant mesothelioma in the UK, 2007
Thorax, November 1, 2007; 62(Suppl_2): ii1 - ii19.
[Full Text] [PDF]

Home page
 The OncologistHome page
G. L. Ceresoli, C. Gridelli, and A. Santoro
Multidisciplinary Treatment of Malignant Pleural Mesothelioma
Oncologist, July 1, 2007; 12(7): 850 - 863.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. L. Ceresoli, P. A. Zucali, A. G. Favaretto, F. Grossi, P. Bidoli, G. Del Conte, A. Ceribelli, A. Bearz, E. Morenghi, R. Cavina, et al.
Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma
J. Clin. Oncol., March 20, 2006; 24(9): 1443 - 1448.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. Pantanowitz, C. N. Otis, A. Munoz, R. Barcelo, G. Lopez-Vivanco, F. Lopez-Rios, M. Ladanyi, B. W.S. Robinson, and R. A. Lake
Malignant Mesothelioma
N. Engl. J. Med., January 19, 2006; 354(3): 305 - 307.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.